Dazodalibep has successfully improved disease activity and symptoms two patient populations with Sjögren’s syndrome in a phase 2 trial, according to a press release from Horizon Therapeutics. The company added that dazodalibep (VIB4920, Horizon), a CD40 ligand antagonist, is currently the only drug in development to achieve the primary endpoint in these populations in a phase 2 trial.
The Company plans to work with the FDA to design a Phase 3 program in moderate-to-high systemic disease activity patients to begin in 2023, ahead of expectations - Horizon Therapeutics plc (Nasdaq: